Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
About this episode
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
(00:32)
Do you mind giving the audience more information about yourself and your background?
(01:53)
Could you please give a brief overview of this assay?
(03:35)
Which patients should have this testing and when should it be performed?
(04:57)
How are the results used in patient care?
(06:59)
Other monoclonal antibody therapies are usually monitored by a combination of drug quantification and analysis of antidrug antibodies. How is this test being offered?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Closing a Diagnostic Gap for Chronic Diarrhea
Answers from the Lab
Unlock the Full Potential of Research Data
Answers from the Lab
A New Mindset for Leading Through Change
Answers from the Lab
Key Components of Innovation Success
Answers from the Lab